According to the American Cancer Society ovarian cancer is expected to account for over 22,000 new cancer diagnoses and more than 14,000 deaths in 2018 in the US alone. In early stages of the disease, ovarian cancer is nearly asymptomatic. Hence, a large portion of the patients present with clinically advanced stages of ovarian cancer. Improving the ability to detect ovarian cancer early is a research priority, given that women diagnosed with localized-stage disease have more than a 90% five-year survival rate.
In this study anti-PAR1 antibody levels in serum samples from 132 healthy donors and 201 patients with ovarian cancer were measured using the kit and method of CellTrend.
The level of antibodies against PAR1 correlates with the risk of relapse or mortality in patients treated with an angiogenesis inhibitor or an inhibitor of EGFR activity. Decreased levels of anti-PAR1 antibodies in samples correlated with a higher risk of relapse or mortality in patients treated with an angiogenesis inhibitor or an inhibitor of EGFR activity. Hence, levels of anti-PAR1 antibodies in samples of patients to be treated with an angiogenesis inhibitor or an inhibitor of EGFR activity are an indicator for response or non-response of a patient.
We also demonstrate for the first time that the decrease of levels of anti-PAR1 antibodies in samples of subjects has a diagnostic and predictive value. It was found that a decrease in the level of antibodies directed against PAR1 in samples of a subject to be diagnosed as compared samples from subjects with proven absence of cancer is indicative of the presence of ovarian cancer as well as for the prediction of response or non-response to a treatment of the ovarian cancer with a drug.
EP-Patent: 3102947